NCT00827281

D-Cycloserine Enhancement of Exposure-Based CBT for Smoking Cessation (DCSSmoking)

D-Cycloserine Enhancement of Exposure-Based CBT for Smoking Cessation

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Boston University Charles River Campus · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study examines whether isolated doses of D-cycloserine enhance the efficacy of CBT for smoking cessation.

Detailed description

In comparison to placebo-augmented cognitive behavioral therapy (CBT), D-cycloserine-augmented CBT will lead to a greater reduction in both short-and long-term point prevalence abstinence as well as time to first smoking lapse and time to smoking relapse.

Conditions

• Smokers

Interventions

Type	Name	Description
DRUG	D-cycloserine	Single dosage prior to sessions 3, 4 \& 5
DRUG	Placebo	Single dosage prior to sessions 3, 4 \& 5

Timeline

• Start date: 2008-08-01
• Primary completion: 2015-07-15
• Completion: 2015-07-15
• First posted: 2009-01-22
• Last updated: 2017-05-01

Locations

1 site across 1 country: United States